Detection of human papillomavirus types 45 and 51 by type-specific polymerase chain reaction

Journal of Virological Methods

Volumn 146, Issue 1-2, 2007, Pages 405-408

  Weyn, Christine ^a   Boulenouar, Selma ^a   Mathys, Vanessa ^a   Vanhoolandt, Julie ^a   Bernis, Aurore ^a   Fontaine, Véronique ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

Diagnosis; HPV 45; HPV 51; Papillomavirus; Type specific PCR

Indexed keywords

PLASMID DNA; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; NONHUMAN; PAPILLOMA VIRUS; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS GENE; VIRUS GENOME;

ALPHAPAPILLOMAVIRUS; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRIDAE;

EID: 35648977516     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2007.08.003     Document Type: Article

References (9)

1. Baay M.F., Quint W.G., Koudstaal J., Hollema H., Duk J.M., Burger M.P., Stolz E., and Herbrink P. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J. Clin. Microbiol. 34 (1996) 745-747
2. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89 (2003) 101-105
3. de Villiers E.-M., Fauquet C., Broker T.R., Bernard H.-U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
4. Fontaine V., Mascaux C., Weyn C., Bernis A., Celio N., Lefevre P., Kaufman L., and Garbar C. Evaluation of combined general primer-mediated PCR sequencing and type-specific PCR strategies for determination of human papillomavirus genotypes in cervical cell specimens. J. Clin. Microbiol. 45 (2007) 928-934
5. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G., and HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
6. Meissner J.D. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki SiHa and HeLa cervical carcinoma cell lines. J. Gen. Virol. 80 (1999) 1725-1733
7. Muñoz N., Castellsagué X., Berrington de González A., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24 Suppl. 3 (2006) (Chapter 1)
8. Pagliusi S.R., Dillner J., Pawlita M., Quint W., Wheeler C.M., and Ferguson M. Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 24 Suppl. 3 (2006)
9. van Doorn L.J., Molijn A., Kleter B., Quint W., and Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 44 (2006) 3292-3298